Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00415597
Status:
COMPLETED
Last Update Posted:
2013-09-20
First Post:
2006-12-21
Brief Title:
Study of Embeda Kadian NT ALO-01 in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Long-Term Open-Label Safety Study of ALO-01 Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Open-Label Safety Study to evaluate the long-term safety of Kadian NT ALO-01 administered for up to 12 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None